Creative Medical Technology Holdings Engages in Warrant Agreements
In a significant development, Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ), a pioneering clinical-stage biotechnology company, has reported its latest agreement regarding warrants. This initiative is part of their ongoing commitment to advancing regenerative immunotherapy solutions. The Company highlighted that it has reached arrangements with several warrant holders for the immediate exercise of outstanding warrants, which allows these holders to convert warrants into an aggregate of 1,116,136 shares of common stock at the current exercise price of $3.75 per share. This upcoming transaction is projected to yield approximately $4.2 million in gross proceeds, bolstering the company’s financial foundation.
Financial Advisory and New Warrants
Roth Capital Partners has stepped in as the financial advisor on this deal, guiding the Company through this process. In return for the holders’ exercise of their existing warrants, Creative Medical Technology Holdings will issue new unregistered warrants that enable the purchase of up to 2,790,340 shares of common stock, again at the price of $3.75 per share. However, there's a notable stipulation: the exercise price may be reduced to the lowest volume-weighted average price (VWAP) of the Company's stock during any trading day within five days of the new warrants' issuance.
Utilization of Proceeds and Transaction Details
The anticipated closing date for this transaction is set for late October 2025, contingent upon standard closing conditions. The net proceeds from this exercise will be strategically directed towards working capital and other essential corporate operations. The Company aims to enhance its resources to continue developing innovative treatments in regenerative medicine.
Company Overview and Mission
Creative Medical Technology Holdings, Inc. stands at the forefront of clinical-stage biotechnology, specializing in regenerative medicine solutions tailored to address a variety of indications. The Company utilizes advanced cell therapy technologies to create transformative treatments that aspire to significantly enhance patient outcomes.
Future Prospects and Commitment
The future looks bright for Creative Medical Technology Holdings. With this successful warrant exercise, they will be better equipped to finance their innovative projects and continue their clinical advancements. The dedication to pioneering research and transformative medical solutions is evident in their strong strategic planning and execution.
Commitment to Compliance
It is essential to mention that the new warrants and shares derived from them will be offered under a private placement, adhering to the applicable exemptions from registration requirements of the Securities Act of 1933. The Company has committed to filing a registration statement with the SEC to cover the resale of the shares stemming from these new warrants.
Frequently Asked Questions
What is the total gross proceeds expected from the warrant exercise?
Approximately $4.2 million is expected from the exercise of the existing warrants.
Who is the financial advisor for this transaction?
Roth Capital Partners is serving as the financial advisor for Creative Medical Technology Holdings in this matter.
What will the proceeds from the warrant exercise be used for?
The proceeds are intended for working capital and general corporate purposes.
What is the exercise price of the new warrants being issued?
The exercise price for the new warrants is set at $3.75 per share.
How does Creative Medical Technology Holdings contribute to medical advancements?
The company is dedicated to pioneering regenerative medicine solutions through advanced cell therapy technologies that aim to improve patient outcomes.
